Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence